Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer.
Tao WuYun YuXinyue TuLihua YeJiaying WangChenjun XieKeke KuangYing YuWeishan ZhugeZhonglin WangRi CuiYihu ZhengPublished in: Journal of ethnopharmacology (2024)
Combined therapy with TBM and oxaliplatin might be an effective therapeutic strategy for some CRC patients.